Variable (Number of studies or subgroups) [Reference numbers] | Mean difference in F&V (95% CI) | P(Z-test) | Heterogeneity I 2% (95% CI) |
---|---|---|---|
Study design | Â | Â | Â |
97.0 (75.5, 118.6) | <0.0001 | 94 (93 to 96) | |
30.8 (9.9, 51.8) | 0.004 | 67 (26 to 88) | |
Ethnicity | Â | Â | Â |
82.5 (47.6, 117.4) | <0.0001 | 61 (0 to 87) | |
Mainly white Caucasians (n = 23) [8, 17, 27–29, 31, 33, 36, 38–42, 44–48] | 87.5 (63.8, 112.8) | <0.0001 | 97 (96 to 98) |
Origin of studies | Â | Â | Â |
America (n = 14) [31, 32, 34, 36–39, 41–43, 45–48] | 112.6 (77.9, 147.3) | <0.0001 | 98 (97 to 98) |
58.1 (45.0, 71.2) | <0.0001 | 49 (0 to 76) | |
61.4 (29.4, 93.4) | 0.0002 | 0 (0 to 90) | |
Sex | Â | Â | Â |
117.6 (75.7 to 159.5) | <0.0001 | 97 (96 to 98) | |
Men and women (n = 16) [8, 27–29, 31–34, 37, 40, 41, 44] | 64.3 (53.6 to 75.0) | 0.0001 | 38 (0 to 66) |
120.4 (-19.9 to 260.8) | 0.09 | 99 (98 to 99) | |
Follow-up time | Â | Â | Â |
4 to 12 months (n = 23) [17, 27, 29, 31, 33, 35, 37–44, 46–49] | 85.6 (59.0 to 112.1) | <0.0001 | 92 (90 to 94) |
13 to 58 months (n = 15) [8, 17, 28, 32–34, 36–38, 45, 47] | 87.0 (53.2 to 120.9) | 0.0001 | 98 (97 to 98) |
Health status | Â | Â | Â |
With health risk factors (n = 15) [8, 28, 31–33, 37, 38, 40, 44, 47] | 82.7 (49.4 to 116.1) | 0.0001 | 95 (93 to 97) |
Healthy participants (n = 11) [17, 27, 29, 34, 36, 39, 41–43, 45],[46, 48] | 91.5 (62.7 to 120.4) | <0.0001 | 96 (94 to 97) |
Mode of intervention delivery | Â | Â | Â |
Face to face (n = 16) [8, 17, 27–29, 32, 36, 38–41, 43–45, 47] | 97.6 (69.2 to 125.9) | <0.0001 | 97 (98 to 99) |
Indirect (for example, telephone, post) (n = 10) [31, 33, 34, 37, 42, 44, 46, 48] | 68.4 (40.8 to 94.5) | <0.0001 | 64 (29 to 82) |